North Carolina Researchers Receive $2,011,500 in Research Funding

Susan G. Komen announces $26 Million Investment in New Research to Find Solutions for Aggressive and Metastatic Breast Cancers, and to Help Communities Most at Risk

North Carolina Researchers Receive $2,011,500 in Research Funding

DALLAS – Sept. 25, 2018 – Susan G. Komen®, the world’s leading breast cancer organization, today announced an additional investment of nearly $26 million to fund 62 new research projects that seek to answer some of the toughest questions facing breast cancer. This new funding is part of the organization’s efforts to reduce the number of breast cancer deaths in the U.S. by 50 percent by 2026 and brings its total research investment to $988 million to date – the largest nonprofit investment outside the U.S. government.

The grants include $2,011,500 in new funding for research at three institutions in North Carolina, bringing Komen’s total research investment in North Carolina to $43,617,501 since 1982.

“This year, Komen is investing in a number of areas that will help us achieve our bold goal and save lives. We are seeking answers to why our current drugs work for some patients, but not all, or why they work at first, but later become ineffective.” said Komen Chief Scientific Advisor, George Sledge, M.D., Chief of Oncology at Stanford University Department of Medicine. “We are also looking into aggressive forms of the disease like triple negative and inflammatory breast cancer, which tend to have poorer outcomes. By investigating novel techniques and therapies, we hope to bring new treatment options to patients.”

The newly announced grants will investigate critical areas in breast cancer research, including (but not limited to) projects focused on one or more of the following:

  • Drug Resistance and Metastasis (40 grants, representing 70 percent of the grants awarded)
  • Triple Negative Breast Cancer (23 grants)
  • New Treatments (38 grants) such as Immunotherapies (9 grants)
  • Health Disparities (8 grants)

This year, Komen’s competitive grant program for young investigators was entirely focused on drug resistance and metastatic disease. “Komen continues its long-standing investment in the next generation of scientists, to ensure that brilliant researchers whose careers are just beginning have funding to pursue their novel ideas,” said Komen Chief Scientific Advisor, Jennifer Pietenpol, Ph.D., Executive Vice President for Research and Director of the Vanderbilt-Ingram Cancer Center at Vanderbilt University Medical Center. “We are proud that this investment includes opportunities for 23 innovative and inspired researchers to lead the way in making breast cancer discoveries that will improve care for all and help save lives.”

“More than 41,000 women and men will lose their lives to breast cancer this year alone. I lost my mother to the disease a few years back, and I myself have been treated for aggressive triple negative breast cancer. The idea that it could impact my daughters is unacceptable,” said Komen President and CEO Paula Schneider. “We all have a personal reason or passion that we support the fight against breast cancer, and we’re proud to invite people to support the work that means the most to them. It will take all of us working together to save lives and ultimately end this disease.”

Komen’s Investments in North Carolina

Komen’s research program is funded in part by contributions from Komen’s nationwide Network of Affiliates, which directs a portion of funds raised locally to Komen’s national research program, while also investing in vital community programs that serve local women and men facing breast cancer.

Since 1997 Komen North Carolina Triangle to the Coast has funded $13,213,318  to community programs serving local women and men, while contributing $5,164,159 to Komen research.

“We are so thankful for the friends, family and neighbors that fight alongside us, helping to reduce the number of breast cancer deaths in North Carolina, both on the ground and through research,” said Pam Kohl, Komen NCTC Executive Director.

In North Carolina, Komen is granting to the following researchers:

Duke University received $36,500 to support the Accelerating Anti-Cancer Drug Development and Validation (AAADV) Workshop and the Duke/Susan G. Komen Fundamentals course for patient advocates. The goal of the Fundamentals course is to introduce patient advocates to the Federal Drug Administration’s (FDA) drug development and approval process. The Fundamentals course will focus on how advocates can work more effectively with all stakeholders in the research process – industry, academia, government and technology – to ensure that the patient voice is incorporated across all conversations and decision making.

Katherine Cook, Ph.D., from Wake Forest University, will receive $450,000 to investigate how diet can contribute to treatment resistance, both in hormonal therapies in ER+ breast cancer and with chemotherapy in triple negative breast cancer (TNBC). The goal of this research is to determine if dietary changes and drugs that block a protein called GRP78 can reduce treatment resistance in breast cancer.

Komen Scholar Donald McDonnell, Ph.D., from Duke University, will receive $400,000 to define the roles of the proteins AGR2 and LYPD3 in breast cancer progression. Dr. McDonnell’s goal is to find new therapeutic targets for patients with ER-positive breast cancers that are resistant to endocrine therapy.

Komen Scientific Advisory Board Member, Lisa Carey, M.D., from The University of North Carolina at Chapel Hill, will receive $400,000 to evaluate how HER2-positive tumors respond to HER2-targeted therapies. This project will integrate and analyze data from over 1300 women participating in six neoadjuvant clinical trials of HER2- targeted therapy.

The University of North Carolina will receive an additional $725,000 to continue the Carolina Breast Cancer Study Phase 3 (CBCS3).  CBCS3, one of the largest population-based studies of women with breast cancer, seeks to identify determinants of disparities in breast cancer clinical outcomes, including biologic, racial, socioeconomic, behavioral factors and identify modifiable factors in clinical care (delivery and access) that address the causes of disparities.

Research has been a cornerstone of Komen’s work since opening its doors in 1982. Komen also works to inspire action through advocacy and public policy, to mobilize communities through support services and opportunities to make a local impact, and provide the care that patients need (including screening, diagnostics, treatment and navigation).

About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. Since its founding in 1982, Komen has funded more than $988 million in research and provided more than $2.2 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. That promise has become Komen’s promise to all people facing breast cancer. Visit or call 1-877 GO KOMEN. Connect with us on social at

About Susan G. Komen® and Komen North Carolina Triangle to the Coast®

Komen was founded in 1982 by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. Komen NCTC is working to better the lives of those facing breast cancer in the local community. Through events like the Komen Triangle Race for the Cure® and Komen Wilmington Race for the Cure ®, Komen NCTC has invested over $13 million in community breast health programs in our 29-county service area and has helped contribute to the more than $956 million invested globally in research For more information, call 919-493-2873 or visit

Grants are contingent upon signed and executed contracts with Komen.